HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $30 price target for the company's stock.
November 28, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Annovis Bio and maintained a $30 price target, potentially influencing investor confidence and the stock's performance.
The reiteration of a Buy rating and the maintenance of a $30 price target by a reputable analyst could lead to increased investor confidence in Annovis Bio, potentially driving the stock price up in the short term. The direct mention of the company and the specific price target provide clear guidance to investors, making this news highly relevant and important for the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100